The study is an interventional, multicentre, prospective, randomized, controlled,
single-blind, comparative trial of two processes for adjusting the inhibitor of calcineurin
(CNI) dosage in lung transplant recipients. Recipients will be stratified by transplant
center and according to the underlying lung disease (affected with cystic fibrosis or not)
and will be randomized to either evaluation of calcineurin activity (CN-a) in combination
with CNI blood levels versus CNI blood levels alone in a 1:1 ratio. The objective is to
compare the proportion of acute rejection that has required a specific curative treatment at
6 months after transplantation between patients in the two groups.